First overseas approval of Sepsivac in Covid treatment in the Philippines

Covid 19 pandemic has stormed the world in past 2 years. Covid 19 is associated with respiratory complications, cytokine storm and sepsis.   

As the world tries to combat this deadly disease, Cadila Pharmaceuticals provided a unique armamentarium to fight this battle – Sepsivac.

On 15 Sep, Sepsivac received its first overseas approval in Philippines. Philippines FDA, looking into efficacy and safety of the product in Covid treatment,  allowed special importation of the Sepsivac on compassionate grounds, which shall strengthen the fight against covid.

 Cadila marketing and formulations teams coordinated with authorities to arrange multiple webinars. 

KOLs from India shared their clinical experience of Sepsivac with Philippines HCPs. The Cadila Pharmaceuticals team worked under the guidance of  Dr. Bakulesh Khamar, Executive Director – Research & Development,  Dr Manjul Joshipura, Senior Vice President, Innovations and New Products, and Mr Mahidhwaj Sisodia, EVP- International Formulations Business, which paved way for the first overseas approval of Sepsivac.      

We are sure this will pave way for Sepsivac to become a Global Brand with Global Approval by a difference in treatment of Covid.